ZA97657B - Ligand directed enzyme prodrug therapy. - Google Patents
Ligand directed enzyme prodrug therapy.Info
- Publication number
- ZA97657B ZA97657B ZA9700657A ZA97657A ZA97657B ZA 97657 B ZA97657 B ZA 97657B ZA 9700657 A ZA9700657 A ZA 9700657A ZA 97657 A ZA97657 A ZA 97657A ZA 97657 B ZA97657 B ZA 97657B
- Authority
- ZA
- South Africa
- Prior art keywords
- prodrug therapy
- directed enzyme
- enzyme prodrug
- ligand directed
- ligand
- Prior art date
Links
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Invalid Beds And Related Equipment (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9601640.7A GB9601640D0 (en) | 1996-01-26 | 1996-01-26 | Ligand directed enzyme prodrug therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA97657B true ZA97657B (en) | 1997-08-01 |
Family
ID=10787646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9700657A ZA97657B (en) | 1996-01-26 | 1997-01-27 | Ligand directed enzyme prodrug therapy. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0876160B1 (de) |
| JP (1) | JP2000504218A (de) |
| AT (1) | ATE187890T1 (de) |
| AU (1) | AU709238B2 (de) |
| DE (1) | DE69700983D1 (de) |
| GB (1) | GB9601640D0 (de) |
| NZ (1) | NZ326436A (de) |
| WO (1) | WO1997026918A2 (de) |
| ZA (1) | ZA97657B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9709421D0 (en) | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| CN1357048A (zh) * | 1998-03-06 | 2002-07-03 | 牛津生物医学(英国)有限公司 | 增强前体药物活化 |
| ES2313779T3 (es) * | 1998-03-13 | 2009-03-01 | The Burnham Institute | Moleculas que migran a diversos organos o tejidos seleccionados. |
| US6232287B1 (en) | 1998-03-13 | 2001-05-15 | The Burnham Institute | Molecules that home to various selected organs or tissues |
| US6174687B1 (en) | 1999-02-26 | 2001-01-16 | The Burnham Institute | Methods of identifying lung homing molecules using membrane dipeptidase |
| GB9907414D0 (en) | 1999-03-31 | 1999-05-26 | Cancer Res Campaign Tech | Improvements relating to prodrugs |
| US6656718B2 (en) | 2000-07-07 | 2003-12-02 | Cancer Research Technology Limited | Modified carboxypeptidase enzymes and their use |
| KR20120068769A (ko) | 2002-07-15 | 2012-06-27 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도 |
| GB0220319D0 (en) | 2002-09-02 | 2002-10-09 | Cancer Res Campaign Tech | Enzyme activated self-immolative nitrogen mustard drugs |
| CA2705152C (en) | 2007-11-09 | 2016-10-11 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
| US10947270B2 (en) * | 2015-08-27 | 2021-03-16 | National Yang-Ming University | Targeted prodrug cytosine deaminase fusion carrier and application thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308483D0 (en) * | 1983-03-28 | 1983-05-05 | Health Lab Service Board | Secretion of gene products |
| DE69232718T2 (de) * | 1991-02-22 | 2003-04-03 | American Cyanamid Co., Madison | Identifizierung eines menschlichen rezeptor-tyrosinkinasegens |
| CA2158745C (en) * | 1993-03-25 | 2007-06-19 | Richard L. Kendall | Inhibitor of vascular endothelial cell growth factor |
| ATE361759T1 (de) * | 1993-07-15 | 2007-06-15 | Cancer Res Campaign Tech | Verbindungen die zur herstellung von protein- tyrosin-kinase-inhibitor-prodrogen verwendet werden können |
| GB9315494D0 (en) * | 1993-07-27 | 1993-09-08 | Springer Caroline | Improvements relating to prodrugs |
| JPH09510352A (ja) * | 1994-03-15 | 1997-10-21 | プリズム ファーマシューティカルズ,インコーポレイティド | 遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子 |
| AU3374795A (en) * | 1994-08-29 | 1996-03-22 | Prizm Pharmaceuticals, Inc. | Conjugates of vascular endothelial growth factor with targeted agents |
| WO1996021416A2 (en) * | 1994-12-30 | 1996-07-18 | Chiron Corporation | Methods and compositions for treatment of solid tumors in vivo |
-
1996
- 1996-01-26 GB GBGB9601640.7A patent/GB9601640D0/en active Pending
-
1997
- 1997-01-24 JP JP9526676A patent/JP2000504218A/ja active Pending
- 1997-01-24 DE DE69700983T patent/DE69700983D1/de not_active Expired - Lifetime
- 1997-01-24 AU AU14530/97A patent/AU709238B2/en not_active Ceased
- 1997-01-24 NZ NZ326436A patent/NZ326436A/xx unknown
- 1997-01-24 WO PCT/GB1997/000221 patent/WO1997026918A2/en not_active Ceased
- 1997-01-24 EP EP97901190A patent/EP0876160B1/de not_active Expired - Lifetime
- 1997-01-24 AT AT97901190T patent/ATE187890T1/de not_active IP Right Cessation
- 1997-01-27 ZA ZA9700657A patent/ZA97657B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE187890T1 (de) | 2000-01-15 |
| EP0876160B1 (de) | 1999-12-22 |
| EP0876160A2 (de) | 1998-11-11 |
| DE69700983D1 (de) | 2000-01-27 |
| WO1997026918A3 (en) | 1997-10-23 |
| JP2000504218A (ja) | 2000-04-11 |
| AU1453097A (en) | 1997-08-20 |
| NZ326436A (en) | 1999-03-29 |
| AU709238B2 (en) | 1999-08-26 |
| WO1997026918A2 (en) | 1997-07-31 |
| GB9601640D0 (en) | 1996-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1996003515A3 (en) | Surface expression of enzyme in gene directed prodrug therapy | |
| AU3649397A (en) | Precise efficacy assay methods for active agents including chemotherapeutic agents | |
| AU1916995A (en) | 4-amino derivatives of mycophenolic acid with immunosuppressant activity | |
| TNSN97009A1 (fr) | 2-oxo- et 2-thio- 1,2- dihydroquinoleinyl-oxazolidinones. | |
| SG144712A1 (en) | Nordihydroguaiartic derivaties for use in treatment of tumors | |
| AU9312198A (en) | Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer | |
| ZA97657B (en) | Ligand directed enzyme prodrug therapy. | |
| WO2001061017A3 (en) | Modified cytokines for use in cancer therapy | |
| MY137303A (en) | Methods for treating proliferative diseases | |
| AU8239298A (en) | Nucleotide-comprising composition | |
| MX9805939A (es) | Formas solidas de administracion, de liberacion instantanea y procesos para su produccion. | |
| AU2356001A (en) | Surface treatment agent for laminated fabric | |
| WO1999064065A3 (en) | Tumour therapy and imaging | |
| WO1998024482A3 (de) | Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung | |
| AU1287001A (en) | Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance | |
| BR0008791A (pt) | Derivados anticonvulsivos, úteis no tratamento de tremor essencial | |
| GB9723824D0 (en) | Cytostatic agents | |
| WO1998050397A3 (de) | Chimäre oligonucleotide und ihre verwendung | |
| ZA977895B (en) | Transdermal therapeutic system having an active compound combination comprising oestriol. | |
| ES2141044A1 (es) | Terapia con oxibutinina. | |
| CA2458872A1 (en) | Human ubiquitin-conjugating enzyme | |
| AU5969500A (en) | 10-formyltetrahydrofolate dehydrogenase as therapeutical agent | |
| EP1800664B8 (de) | Pharmazeutische Zubereitungen zur parenteralen Verabreichung enthaltend Epothilon | |
| MX9701031A (es) | Utilizacion de la selegilina para el tratamiento de enfermedades epilepticas. | |
| AU2143597A (en) | The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias |